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The use of chemotherapy for patients with cancer has increased
markedly in the UK over the past few years (Richards and Parrott,
1996). In part this relates to the increased use of adjuvant
chemotherapy following surgery for breast and colorectal cancer.
Much of the increase, however, relates to the treatment of patients
with advanced cancer. In the 1980s the use of chemotherapy was,
in general, limited to patients with haematological malignancies,
small cell lung cancer, breast cancer, ovarian cancer and rare
cancers such as testicular teratoma and choriocarcinoma. More
recently, chemotherapy has been given to a much larger number of
patients with advanced stages of several common cancer types,
including colorectal cancer, oesophagogastric cancer, non-small
cell lung cancer and bladder cancer.
At least 12 new anticancer agents have been licensed in the UK
in the past 3 years (Table 1) and more are expected to be licensed
in coming months. Although in some instances these new treat-
ments may be substituted for existing treatments, in other cases
they are recommended as additional treatments. For example,
there is likely to be an increase in the use of chemotherapy for non-
small cell lung cancer (NSCLC) where none would have been
given previously. Patients with advanced colorectal cancer whose
disease has progressed following first-line chemotherapy may now
be offered second-line treatment where none was previously avail-
able. The potential cost to the NHS of the new cytotoxic drugs
alone could be considerable. The increase in total costs of care
(including the costs of inpatient stays, day-case attendances, inves-
tigations, etc) if all these treatments become incorporated into
clinical practice will be substantially greater.
Although expenditure on chemotherapy has risen considerably
in the 1990s the allocation of additional resources has not kept
pace with demand, especially for the new treatments. Clinicians
find themselves restricted, either by Health Authorities or by
provider Trusts, in the use of licensed treatments which they feel
are in the best interests of an individual patient. Against this,
Health Authorities have a duty to ensure that scarce resources are
used equitably to meet the needs of the local population as a
whole.
This paper outlines an approach to the prioritization of new
treatment for advanced cancer developed jointly by clinicians and
health authorities in South London. Our first aim was to achieve
consensus regarding the relative effectiveness of a range of
chemotherapy treatments given to patients with different types of
cancer. Secondly, we wished to assess the strength of current
evidence supporting the relative effectiveness rating for each treat-
ment. Thirdly, we wished to present the information in a format
which would enable health authorities to make rational decisions
on the future allocation of resources.
In the future the National Institute for Clinical Excellence
(NICE) may well have an active role in providing guidance on
effectiveness and resource allocation in the UK. However, in the
medium term they have to be addressed by clinicians and health
authorities.
METHODS
Scope of project
The scope of the project was limited to treatment given for
advanced cancer, as this encompasses the licensed indications of
all of the new cytotoxic agents. Treatments given with curative
intent (e.g. for some patients with acute leukaemias, lymphomas
and teratoma) were excluded from this process as were adjuvant
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ments for patients with advanced cancer and supportive treatments
given to patients receiving chemotherapy (e.g. antiemetics, anti-
biotics and colony-stimulating factors) have not been considered at
this stage.
Assessment of the relative effectiveness of treatments
The main objectives of giving anticancer treatments to patients
with advanced cancer are to optimize quality of life (QoL) and,
where possible, to prolong life. The overall effectiveness of a treat-
ment cannot be determined by any single existing outcome
measure, as none combines quantity and quality of life. The
measures that are currently reported in clinical trials include:
• Survival: Does the treatment prolong median survival and if so
by how long? The proportion of patients surviving for a
specific interval after the initiation of treatment (e.g. 1 year,
2 years) is also sometimes reported.
• Time to progression: Does the treatment prolong the median
time to disease progression and if so by how long?
• Response rate: What proportion of patients experience an
objective response to treatment, measured in terms of a reduc-
tion in size of measurable lesions? This is principally a
measure of drug activity against the cancer, but has been
shown to correlate with improvement in QoL (Baum et al,
1980; Coates et al, 1987; Kaasa et al, 1988; Glimelius et al
1989; Ramirez et al 1998).
• Quality of life: How does the treatment impact on patients’
QoL? The antitumour effect of the treatment may enhance
QoL, while its toxicity may have adverse consequences for
QoL. Several QoL measures have been specifically developed
and validated for use in clinical research trials for patients with
cancer (de Haes et al 1990; Aaronson et al 1993; Cella et al
1993).
Meta-analyses relating to the effectiveness of ‘standard’ treat-
ments were used where available (NHS Executive, 1996; 1997;
1998; NSCLC Collaborative Group, 1995; Lilenbaum et al, 1998;
Advanced Ovarian Cancer Trialists Group 1991; 1998). Reviews
of the current published evidence related to the effectiveness
of new treatments were undertaken independently by a senior
Oncology Pharmacist (MS) and by consultants in Public Health
Medicine. The information from these reviews was scrutinized
by a panel of oncologists with extensive clinical and research
expertise related to the relevant tumour types, to identify any
important omissions or inaccuracies.
Relative effectiveness ratings were derived at consensus meet-
ings, involving clinicians and health authority representatives,
rather than being based solely on analyses of the published
evidence. This approach was adopted for several reasons. First, we
wished to combine the evidence relating to survival and quality of
life into a single rating. Secondly, it was recognized that outcomes
reported in the research literature apply to selected groups of
patients included in clinical trials and may differ from those
observed in routine clinical practice (Gregory et al, 1993). Thirdly,
many early treatments for advanced cancer were not assessed in
the context of randomized controlled trials (RCTs) with a
control arm. The evidence is therefore suboptimal, but pragmatic
decisions still need to be made to inform practice.
Participants in the consensus meetings were asked to consider
where each treatment should be placed across a spectrum of effec-
tiveness for palliative treatments, ranging from no benefit at one
end to highly effective at the other. An example of a treatment with
no benefit would be one with no impact on survival and where the
toxicity, on average, offset any benefit in terms of relief of cancer-
related symptoms. A four category scale (A – D) was used to cate-
gorize individual treatments, with the most effective treatments
being assigned to category A and the least effective to category D.
Standard chemotherapy for small cell lung cancer (SCLC) was
taken as an example of a highly effective palliative/life-prolonging
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Table 1 New treatments
Generic Trade Cost per Tumour types for which the
name name cyclea drug is licensedb
£
Docetaxel Taxotere 1560 Breast cancer
Fludarabine Fludara 760 B cell chronic lymphocytic
leukaemia
Gemcitabine Gemzar 1030 Non-small cell lung cancer
Adenocarcinoma of pancreas
Interferon ac Various haematological
malignancies
Irinotecan Campto 760 Colorectal cancer
Liposomal Caelyx 1070 AIDS-related Kaposi sarcoma
Doxorubicin
Paclitaxel Taxol 1300 Ovarian cancer
Breast cancer
Raltitrexed Tomudex 410 Colorectal cancer
Rituximab Mabthera 1900 Follicular lymphoma
Topotecan Hycamtin 1830 Ovarian cancer
Vinorelbine Navelbine 175 Non-small cell lung cancer
Breast cancer
Temozolamide Temodal 1380 Glioblastoma multiforme
a Costs per cycle have been calculated for a patient with a body surface area of 1.7 m2 and are based on list
prices including VAT. Cycles are typically repeated every 3–4 weeks, the total number of cycles depending
on the patient’s response to treatment and on toxicity; b Licensed indications for several of the new drugs are
restricted to patients whose disease is resistant to standard treatments; c Interferon a – cost per cycle is not
shown as the recommended dosages vary for different indicationstreatment, which is widely recommended by clinicians (category
A). The large majority of patients receiving treatment experience
symptomatic benefit and improvements in QoL. Median survival
is thought to be prolonged by about 9 months (based on compar-
isons with historical controls).
When new treatments were being compared with existing treat-
ments a ‘comparative effectiveness’ rating was assigned (A – D).
This represents the magnitude of the additional benefit of the new
treatment over the established treatment:
A = Prolongation of median survival by > 9 months together
with improvement in quality of life
B = Prolongation of median survival by 3–6 months with
improvement in quality of life
C = Improvement in quality of life but little or no impact on
median survival
D = Minimal impact on quality of life and no impact on
median survival
Strength of evidence
The strength of current evidence regarding the efficacy of new
treatments has to be clearly differentiated from the magnitude of
benefit/effectiveness. The following scale is used in this paper to
denote strength of evidence.
a+ = Data from a meta-analysis or from at least two high-
quality RCTs
a– = One high-quality RCT and supporting non-randomized
(phase II) data
b = One poor-quality RCT and/or several phase II studies
g = Single phase II study only
H = Survival evidence based on comparisons with historical
controls.
Standard treatments
For the purposes of this project, ‘standard’ treatments were
defined as those regimens already used in clinical practice in
South London which do not involve any of the recently licensed
agents. The agents used in these regimens have been available for
at least 10 years, although some of the combinations have only
been introduced more recently. The term ‘standard’ should not be
taken to mean that all patients with the relevant cancer should be
recommended to receive the treatment. Rather, that these regimens
have become accepted as appropriate for selected patients with the
relevant cancer type.
RESULTS
Standard treatments
The list of treatments shown in Table 2 is not exhaustive, but
relates to those cancer types for which most of the new treatments
have been licensed.
Effectiveness ratings of ‘A’ were assigned to the first-line treat-
ment of SCLC and follicular lymphoma. For breast cancer, first-
line treatments were rated as ‘B’ and second-line treatment as ‘C’.
This reflects the lower response rates and shorter times to progres-
sion normally observed following second-line treatment. Standard
first-line treatments for NSCLC were considered to be broadly
similar in terms of effectiveness to standard second-line treatments
for breast cancer.
The strength of evidence related to the individual effectiveness
ratings for standard treatments largely reflects the era in which the
respective treatments were introduced into clinical practice. Thus,
for SCLC and breast cancer the evidence is based on extensive
observational data related to response rates, time to progression and
QoL parameters – but prolongation of life is not directly quantifiable
owing to the lack of RCTs with a control arm. In contrast, sufficient
studies of this type have been reported for patients with colorectal
cancer and NSCLC to enable meta-analyses to be undertaken.
New treatments
Table 3 shows the effectiveness and strength-of-evidence ratings
for some of the newly licensed treatments. For most of the new
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Table 2 Effectiveness and strength of evidence for standard treatments
Cancer type Setting Regimen(s) Effectiveness Strength-of-evidence
rating rating
Small cell lung First-line PE/CAV A b (H)
cancer
Non small cell First-line MIC/MVP C a+
lung cancer
Breast cancer First-line FAC/FEC B b
Second-line CMF/MV C b
Colorectal First-line LVFU B a+
cancer
Stomach cancer First-line ECF B a–
Ovarian cancer First-line CC/CAP/Carbo Ba a+
Follicular First-line Chlorambucil A b
lymphoma
Second-line CVP/CHOP B b
a Denotes effectiveness in comparison with non-platinum drug regimens; PE = cisplatin, etoposide; CAV =
cyclophosphamide, doxorubicin, vincristine; MIC = mitomycin C, ifosfamide, cisplatin; MVP = methotrexate,
vinblastine, cisplatin; FAC = fluorouracil, doxorubicin, cyclophosphamide; FEC = fluorouracil, epirubicin,
cyclophosphamide; CMF = cyclophosphamide, methotrexate, fluorouracil; MV = mitomycin C, vinblastine; LVFU =
leucovorin-primed fluorouracil; ECF = epirubicin, cisplatin, fluorouracil; CC = cisplatin, cyclophosphamide; CAP =
cisplatin, doxorubicin, cyclophosphamide; Carbo = carboplatin CVP = cyclophosphamide, vinblastine, prednisolone;
CHOP = cyclophosphamide, doxorubicin, vincristine, prednisolonetreatments evidence of effectiveness is based on the results of
randomized controlled trials where the comparator is an existing
treatment. For these treatments the effectiveness ratings are based
on the additional benefit observed compared with that of the
existing treatment. The overall effectiveness of these new treat-
ments (in comparison with best supportive care) can only be
inferred. However, where existing treatments have been demon-
strated to be more effective than best supportive care it might be
argued that the overall effectiveness would be somewhat greater.
Only one new treatment (paclitaxel and platinum for first-line
treatment of ovarian cancer) was rated as ‘A’ in comparison with
standard treatments. The strength of evidence supporting this was
‘a+’. Rituximab for relapsed follicular lymphoma was also given a
high rating (A/B), but this was based on observational data (i.e.
strength of evidence = b). Several other treatments were rated as
‘B’ or borderline B/C.
Liposomal doxorubicin was rated as ‘C’ for the treatment of
Kaposi sarcoma, the lower toxicity associated with the new
compound giving it an advantage over standard treatment with
doxorubicin. Raltitrexed was rated C/D as there is no evidence of
prolongation of life in comparison with leucovorin-primed fluoro-
uracil, but the convenience of administration may be advantageous
in some circumstances.
DISCUSSION
The management of advanced cancer presents difficult decisions
for patients and clinicians, quite apart from any considerations of
financial cost. The treatments currently available frequently have
only limited effectiveness and may have considerable toxicity.
Predicting the levels of benefit and side-effects that individual
patients will experience is extremely difficult, if not impossible.
Clinicians have to be able to present the available evidence clearly,
so that patients can weigh up from their own perspective the poten-
tial advantages and disadvantages of particular treatment options.
Those responsible for clinical decision-making need to be mindful
that patients facing a life-threatening illness may weigh the
evidence differently from those in good health. In a study based on
hypothetical scenarios patients with cancer were much more likely
to opt for radical treatment with minimal chance of benefit than
people who did not have cancer, including medical and nursing
professionals (Slevin et al, 1990). In a recent study in the USA,
patients who had received cisplatin-based chemotherapy for
advanced NSCLC were asked whether they would accept
chemotherapy given a range of hypothetical scenarios relating
to toxicity and survival. Patients’ willingness to accept chemo-
therapy varied widely, some accepting treatment for a survival
benefit of only 1 week, others not accepting treatment even for 24
months prolongation of life. However, most reported that they
would accept chemotherapy if it substantially reduced symptoms
without prolonging life (Silvestri et al, 1998).
The evidence available to clinicians on the benefits and toxici-
ties of individual treatments includes both the published literature
from clinical trials and their own experience gained from treating
previous patients. The approach adopted for this project represents
an attempt to formalize this process by combining an objective
assessment of the research evidence with the experience of a group
of clinicians.
Decisions regarding the delivery of chemotherapy do not rest
with clinicians and patients alone. Health authorities have to eval-
uate health care needs and competing claims for service develop-
ments across all health services, against a background of limited
resources. In relation to advanced cancer health authorities have to
decide whether additional resources will be made available both
for extensions in the use of ‘standard’ chemotherapy treatments
and for the introduction of new therapies. The potentially
competing claims for resources for other palliative interventions
and for specialist palliative care also have to be considered. At
present, individual health authorities across the UK are under-
taking separate reviews of the effectiveness of each of the newly
licensed anticancer treatments and are making individual decisions
on the allocation of resources. Variations in resource allocations
have led to concerns regarding rationing by postcode.
The approach described in this paper involved a partnership
between NHS Trusts and Health Authorities (Secretary of State for
Health, 1997) and has, we believe, provided a rational basis for
resource allocation. We have been able to achieve broad consensus
between clinicians and commissioners in South London regarding
the relative effectiveness of different chemotherapy treatments and
the strength of evidence supporting these ratings. Those respon-
sible for resource allocation have informed us that they find this
approach helpful for their understanding both of the clinical issues
and the large amount of data from individual studies. Additional
funding has been made available based largely on the estimated
costs of providing new treatments rated A or B for effectiveness
and with an a+ or a– for strength of evidence. However, at
an individual patient level decisions rest with provider units,
thus avoiding blanket bans on specific treatments. Activity and
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Table 3 Assessment of new treatments
Disease Setting New treatment Comparator Effectiveness of new Strength of evidence
treatment
Ovarian cancer First-line Paclitaxel and platinum Various ‘standard’ Aa a+
Second-line Topotecan Platinum Ba a–/b
Follicular lymphoma Third-line Rituximab – A/B b
Breast cancer Second-line Docetaxel MV Ba a–
Colorectal cancer First-line Raltitrexed LVFU C/Da a+
Second-line Irinotecan Best supportive care B a–
Renal cancer First-line Interferon a Medroxyprogesterone acetate Ba a–
Kaposi sarcoma Second-line Liposomal doxorubicin Doxorubicin Ca a+
Non-small cell lung First-line Vinorelbine/cisplatin Cisplatin Ba a+
cancer
Second-line Gemcitabine Best supportive care D a+
a Denotes effectiveness in comparison with existing treatment; MV = mitomycin C, vinblastine; LVFU = leucovorin-primed fluorouracil1272 JSJ Ferguson et al
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outcomes related to the use of each of these new treatments are
being audited. We believe that the methods and results reported in
this paper should be transferable to other health care systems.
However, the relative priority given to chemotherapy for advanced
cancer may well differ between countries leading to the adoption
of different thresholds for funding of new treatments.
Our approach has some similarities to that reported from
Greater Manchester (Foy et al 1999), but also has some important
differences. In particular we evaluated the magnitude of benefit
and the strength of evidence separately, according to predefined
scales, rather than simply categorizing treatments as being of
proven clinical effectiveness over and above existing treatments.
Unlike the Manchester Group we did not define a specific
threshold for funding at our consensus meetings, thus avoiding
pressure to move the threshold up or down.
We readily acknowledge that our work to date has limitations.
Any method which attempts to combine effects on length of life
and quality of life in a single measure involves value judgements
regarding the relative importance of the two dimensions. In prac-
tice, most chemotherapy agents which have a significant impact on
survival also have quality of life benefits, as both effects are medi-
ated through a reduction in tumour burden. Some treatments may,
however, have significant QoL benefits with only marginal effects
on survival (e.g. through having lower toxicity than a previous
treatment, but with both treatments having an equivalent impact on
survival).
As yet we have only conducted limited work in relation to the
assessment of costs. It is reasonably simple to estimate the likely
additional costs per patient of the chemotherapy agents per se (see
Table 1). It is also possible to estimate the likely number of
patients within a given population who might match the licensed
indications for the treatments. It is more difficult to estimate the
proportion of patients who would wish to receive the treatment,
particularly for treatments at the lower end of the effectiveness
scale. The overall costs of treatment are likely to be substantially
greater than the costs of the chemotherapy agents alone (Richards
et al, 1993). Although the drug costs are highly visible the impact
on hospital bed usage and on outpatient and day-case attendances
(among other factors) may be of equal importance. Work which is
currently in progress for the development of chemotherapy
Healthcare Resource Groups (HRGs) will hopefully address this.
The costs that would be incurred in caring for patients who do not
receive a specific treatment also need to be considered.
At present the scope of this project has been limited to
chemotherapy and biological therapies for advanced cancer.
Extending the work to incorporate other new treatments for
advanced cancer, such as new endocrine agents or new approaches
in the delivery of radiotherapy should be quite simple. We believe
that comparisons could also potentially be made with treatments
for other advanced incurable illnesses, given to patients with
limited life-expectancy. However, for treatments given with cura-
tive intent other approaches such as quality-adjusted life-years
(QALYs) gained are more appropriate.
We hope that this paper will stimulate debate regarding the use
of chemotherapy in patients with advanced cancer. Do oncologists,
public health physicians and the pharmaceutical industry agree
with our ratings of effectiveness? At what point should the
strength of evidence be deemed adequate for decisions to be made
regarding resource allocation? It might be argued that at least two
RCTs are needed – the first being seen as hypothesis-generating
and the second as providing confirmatory evidence. This standard
may well be unachievable, especially for treatments given for rare
cancers. The ethical and practical issues of recruiting patients with
advanced cancer into a second RCT when the positive results of
one RCT are known should also be considered.
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